Breaking News Instant updates and real-time market news.

GLPG

Galapagos NV

$87.67

0.02 (0.02%)

, GILD

Gilead

$67.80

-0.28 (-0.41%)

14:46
05/07/17
05/07
14:46
05/07/17
14:46

Galapagos reports presentation of Phase 2 filgotinib data

Galapagos (GLPG) announced the presentation of three posters from the Phase 2 FITZROY study of the investigational agent filgotinib in Crohn's Disease, at Digestive Disease Week. The presentations include "Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the Phase 2 FITZROY study," "Maintenance of clinical effect in patients with moderate-to-severe Crohn's disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the Phase 2 FITZROY study," and "Filgotinib, a JAK-1 Selective Inhibitor, Significantly Reduces Gut Tissue pSTAT3 in Crohn's Disease Patients." Galapagos and Gilead (GILD) entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications.

GLPG

Galapagos NV

$87.67

0.02 (0.02%)

GILD

Gilead

$67.80

-0.28 (-0.41%)

  • 16

    May

  • 06

    Jun

GLPG Galapagos NV
$87.67

0.02 (0.02%)

03/01/17
NOMU
03/01/17
INITIATION
Target $87
NOMU
Buy
Galapagos NV initiated with a Buy at Nomura
Nomura initiated Galapagos NV with a Buy and a $87 price target.
04/17/17
NOMU
04/17/17
NO CHANGE
Target $121
NOMU
Buy
Galapagos NV price target raised to $121 from $87 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised Galapagos NV's price target to $121 telling investors the baricitinib CRL is a positive for the company as it may limit first-mover advantage versus figotinib. Marai now expects at lest a 1-year delay in baricitinib's approval, trimming the potential lead time on US market over filgotinib. The analyst rates Galapagos NV a Buy.
04/24/17
JANY
04/24/17
DOWNGRADE
JANY
Sell
Galapagos NV downgraded to Sell from Buy at Janney Capital
04/24/17
04/24/17
DOWNGRADE
Target $73

Sell
Janney says Galapagos NV 'priced to perfection,' cuts two notches to Sell
As previously reported, Janney Capital analyst Debjit Chattopadhyay downgraded Galapagos NV (GLPG) to Sell from Neutral, stating that while the baricitinib setback suffered by competitors Incyte (INCY) and Eli Lilly (LLY) was "obviously great news," filgotinib is still more than 2 years from commercialization and over seven years away from peak sales. The majority of the positives are already reflected in the stock, even "generously" assuming peak sales for filgotinib above $3B, said Chattopadhyay, who has a $73 fair value estimate on Galapagos shares, which closed Friday at $85.84.
GILD Gilead
$67.80

-0.28 (-0.41%)

03/20/17
JEFF
03/20/17
NO CHANGE
JEFF
Buy
Jefferies uncovers 'unnoticed' positive NASH data coming from Gilead
Jefferies analyst Brian Abrahams said his review of titles for the upcoming EASL meeting of the International Liver Congress appears to indicate that Gilead's ACC inhibitor GS-0976, which he calls "one of [the company's] least-talked-about assets in NASH," demonstrated significant positive effects in an as-yet-unreported phase 2 study. The analyst, who calls the presentation "unnoticed" and "not broadly discussed," believes the study may meaningfully de-risk a second NASH asset and could set the stage for increasing enthusiasm around Gilead's NASH program over the next 12 months. Abrahams keeps a Buy rating on Gilead shares. The ILC meeting is being held from April 19 to 23 in Amsterdam.
04/21/17
PIPR
04/21/17
NO CHANGE
PIPR
Overweight
Piper Jaffray 'encouraged' by Gilead ACC inhibitor data in NASH
Piper Jaffray analyst Joshua Schimmer said Gilead's GS-0976 program in the treatment of NASH are the company's "most interesting" and the just announced data for the ACC inhibitor in a 10 patient study are very encouraging. The analyst, who continues to believe that reducing lipids is a key component for treating NASH, added that long term safety for inhibition of ACC will be necessary before he can have confidence in the program's potential. He keeps an Overweight rating on Gilead shares.
04/25/17
WELS
04/25/17
NO CHANGE
WELS
Gilead Q1 results poised to beat expectations, says Wells Fargo
After analyzing prescription data for January and February, Wells Fargo says that prescriptions of Gilead's HIV and HCV drugs were tracking ahead of expectations. The firm says the company's Q1 results appear on track to beat expectations.
04/25/17
JMPS
04/25/17
NO CHANGE
JMPS
Johsnson &Johnson data positive for Achillion, says JMP Securities
JMP Securities analyst Liisa Bayko says that data on a triple combination HCV treatment presented by Johnson & Johnson (JNJ) yesterday is positive for Achillion (ACHN). The analyst noted that the triple combination includes Achillion's odalasvir and that the six week treatment regimen is shorter than the eight weeks required for Gilead's (GILD) Harvoni. The analyst says that Achillion's stock dropped sharply yesterday because there was disappointment over the combination's efficacy in genotype 3 patients. However, she says that such patients only represent 10% of the total, and she says that Achillion can "conservatively" obtain peak royalty revenue of about $100M from its drug. Bayko keeps a $13 price target and an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$272.57

-0.69 (-0.25%)

, SPX

S&P 500

$0.00

(0.00%)

21:03
05/22/18
05/22
21:03
05/22/18
21:03
Periodicals
Trump to propose further tax cuts before November, Reuters reports »

President Trump has…

SPY

SPDR S&P 500 ETF Trust

$272.57

-0.69 (-0.25%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBK

FB Financial

$42.26

-1.36 (-3.12%)

20:49
05/22/18
05/22
20:49
05/22/18
20:49
Syndicate
FB Financial 3.2M share Secondary priced at $41.25 »

JPMorgan and Stephens…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 24

    Sep

  • 23

    May

MYOK

MyoKardia

$50.45

2.15 (4.45%)

20:48
05/22/18
05/22
20:48
05/22/18
20:48
Syndicate
MyoKardia 3.75M share Secondary priced at $49.00 »

JPMorgan, BofA/Merrill,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

TWOU

2U

$91.64

-3.86 (-4.04%)

20:47
05/22/18
05/22
20:47
05/22/18
20:47
Syndicate
2U 3.3M share Secondary priced at $90.00 »

Goldman Sachs and Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

ARDX

Ardelyx

$4.50

-1.15 (-20.35%)

20:46
05/22/18
05/22
20:46
05/22/18
20:46
Syndicate
Ardelyx 12.5M share Secondary priced at $4.00 »

Jefferies and Leerink…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

  • 23

    May

LOW

Lowe's

$85.74

-1.63 (-1.87%)

, TGT

Target

$75.42

-1.44 (-1.87%)

20:25
05/22/18
05/22
20:25
05/22/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

LOW

Lowe's

$85.74

-1.63 (-1.87%)

TGT

Target

$75.42

-1.44 (-1.87%)

TIF

Tiffany

$102.26

-0.96 (-0.93%)

RL

Ralph Lauren

$116.67

-0.41 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

  • 23

    May

  • 24

    May

  • 07

    Jun

  • 19

    Jun

  • 26

    Jun

INFO

IHS Markit

$51.28

-0.32 (-0.62%)

20:02
05/22/18
05/22
20:02
05/22/18
20:02
Hot Stocks
IHS Markit expands MarkitSERV trade reporting solution in Asia and Europe »

IHS Markit (INFO)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDAY

Ceridian

$34.31

-0.885 (-2.51%)

19:54
05/22/18
05/22
19:54
05/22/18
19:54
Recommendations
Ceridian analyst commentary  »

Ceridian price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

RMTI

Rockwell Medical

$5.94

-0.06 (-1.00%)

19:20
05/22/18
05/22
19:20
05/22/18
19:20
Hot Stocks
Rockwell Medical president, CEO Chioini terminated from his positions »

Rockwell Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,582.10

-3.45 (-0.22%)

19:16
05/22/18
05/22
19:16
05/22/18
19:16
Periodicals
Amazon.com has banned some shoppers who make excessive returns, WSJ says »

Amazon.com has banned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

CTRP

Ctrip

$43.46

0.48 (1.12%)

, HPE

HP Enterprise

$17.49

-0.01 (-0.06%)

19:03
05/22/18
05/22
19:03
05/22/18
19:03
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Ctrip…

CTRP

Ctrip

$43.46

0.48 (1.12%)

HPE

HP Enterprise

$17.49

-0.01 (-0.06%)

ARCO

Arcos Dorados

$7.55

0.35 (4.86%)

MET

MetLife

$48.48

0.405 (0.84%)

RRGB

Red Robin

$57.80

-2.9 (-4.78%)

TCS

Container Store

$8.23

0.68 (9.01%)

URBN

Urban Outfitters

$41.21

-1.09 (-2.58%)

CRIS

Curis

$0.53

0.0211 (4.13%)

IBTX

Independent Bank

$77.85

-0.7 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 30

    May

  • 05

    Jun

  • 11

    Jun

  • 12

    Jun

  • 10

    Jul

  • 10

    Sep

  • 24

    Sep

EADSY

Airbus

$0.00

(0.00%)

, BA

Boeing

$355.06

-8.89 (-2.44%)

18:59
05/22/18
05/22
18:59
05/22/18
18:59
Periodicals
Airbus says plane subsidies over, U.S. rejects notion, WSJ says »

The U.S. and EU have…

EADSY

Airbus

$0.00

(0.00%)

BA

Boeing

$355.06

-8.89 (-2.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

QTNA

Quantenna Communications

$14.94

-0.13 (-0.86%)

18:43
05/22/18
05/22
18:43
05/22/18
18:43
Initiation
Quantenna Communications initiated at William Blair »

Quantenna assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

ALGT

Allegiant Travel

$153.95

-5.15 (-3.24%)

18:42
05/22/18
05/22
18:42
05/22/18
18:42
Hot Stocks
Allegiant Travel announces tentative dispatchers contract agreement with IBT »

Allegiant announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

EA

Electronic Arts

$132.18

-0.73 (-0.55%)

18:30
05/22/18
05/22
18:30
05/22/18
18:30
Recommendations
Electronic Arts analyst commentary at Baird »

Electronic Arts'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POOL

Pool Corp.

$145.96

-3.74 (-2.50%)

18:22
05/22/18
05/22
18:22
05/22/18
18:22
Hot Stocks
Pool Corp. director Stokely sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

  • 13

    Jun

RRGB

Red Robin

$57.80

-2.9 (-4.78%)

18:16
05/22/18
05/22
18:16
05/22/18
18:16
Recommendations
Red Robin analyst commentary at Stephens »

Red Robin Q1 traffic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

BGS

B&G Foods

$26.50

-0.75 (-2.75%)

18:11
05/22/18
05/22
18:11
05/22/18
18:11
Hot Stocks
B&G Foods increases dividend 2.2% to 47.5c »

B&G Foods announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

CTRP

Ctrip

$43.46

0.48 (1.12%)

18:05
05/22/18
05/22
18:05
05/22/18
18:05
Hot Stocks
Breaking Hot Stocks news story on Ctrip »

Ctrip falls over 3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 10

    Sep

CTRP

Ctrip

$43.46

0.48 (1.12%)

18:05
05/22/18
05/22
18:05
05/22/18
18:05
Earnings
Ctrip reports Q1 adjusted earnings per ADS 55c, may not compare to consensus 16c »

Reports Q1 revenue $1.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 10

    Sep

PLBC

Plumas Bancorp

$28.00

(0.00%)

18:02
05/22/18
05/22
18:02
05/22/18
18:02
Hot Stocks
Plumas Bank agrees to purchase Carson City branch of Mutual of Omaha Bank »

Plumas Bank, the wholly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRP

Ctrip

$43.46

0.48 (1.12%)

18:02
05/22/18
05/22
18:02
05/22/18
18:02
Earnings
Breaking Earnings news story on Ctrip »

Ctrip sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 10

    Sep

CRIS

Curis

$0.53

0.0211 (4.13%)

17:56
05/22/18
05/22
17:56
05/22/18
17:56
Hot Stocks
Curis announces 1-for-5 reverse stock split »

Curis announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCS

Container Store

$8.23

0.68 (9.01%)

17:47
05/22/18
05/22
17:47
05/22/18
17:47
Hot Stocks
Container Store drops 12% after Q4 EPS lower than estimates »

Shares of the Container…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

URBN

Urban Outfitters

$41.21

-1.09 (-2.58%)

17:45
05/22/18
05/22
17:45
05/22/18
17:45
Hot Stocks
Urban Outfitters sees Q2 SSS so far stronger than Q1 »

Comment taken from Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.